CSL Behring announces results of rIX-FP Phase We study on hemophilia B CSL Behring today announced the outcomes of a Phase I study evaluating recombinant fusion proteins linking coagulation Aspect IX with albumin in patients with severe hemophilia B. CSL Behring, in collaboration using its parent organization, CSL Limited , can be developing rIX-FP for the prophylaxis and treatment of bleeding episodes in individuals with congenital Factor IX deficiency within the PROLONG-9FP clinical study plan http http://tadacip20mg.org . Related StoriesPresident and CEO of Proteins Sciences elected as 2015 Fellow of the International Culture for VaccinesRice researchers solve long-standing up mystery about hemophilia proteinNew Global Energy and International Sustainability Group agree to manufacture, distribute MoringaUP Protein Bars Hemophilia B can be a rare and serious bleeding disorder that prevents normal blood clotting and requires frequent infusion of Aspect IX concentrates to revive clotting ability, stated Elena Santagostino, M.D., Ph.D., Professor in the Medical College of Clinical and Experimental Hematology at the University of Milan/IRCCS Maggiore Medical center.
today reported financial outcomes and recent accomplishments for the first quarter of 2012. Initial Quarter Financial Results For the one fourth ended March 31, 2012, total operating expenses were $18.1 million in comparison to $20.1 million for the same period in 2011. Net loss attributable to common shareholders reduced 66 percent to $17.4 million for the quarter ended March 31, 2012 compared to a net reduction attributable to common shareholders of $51.0 million for the same period in 2011. The reduction in net loss due to CTI’s common shareholders is definitely primarily because of a decrease in deemed dividends and total operating expenditures. CTI had approximately $27.